To Be Discontinued Solution Antiviral
Maraviroc Solution · 234 days since initial FDA posting
Brand: SELZENTRY
FDA lists Maraviroc Solution as To Be Discontinued (ViiV Healthcare Company).
No availability text on this FDA row.
Maraviroc Solution: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Maraviroc Solution
- Manufacturer
- ViiV Healthcare Company
- Dosage Form
- Solution
- Presentation
- Selzentry, Solution, 20 mg/mL Oral Solution Kit | 230 mL Oral Solution per Bottle | 1 Bottle per Carton (NDC 49702-260-55)
- Package NDC
- 49702-260-55
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Jan 20, 2026
- Last Updated
- Jan 20, 2026
- Therapeutic Category
- Antiviral
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
The anticipated date that GSK will cease distribution of the product is approximately August 1, 2026.
FDA reason on file: The anticipated date that GSK will cease distribution of the product is approximately August 1, 2026. General shortage guidance lives on the tracker hub.